FDA acknowledges resubmission of Merck’s NDA for ezetimibe and atorvastatin tablets

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine.

Read more...